FRIENDSWOOD, Texas, December 01, 2023--Castle announced the publication of a new study that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma.
Last week, Castle Biosciences, Inc. ( NASDAQ:CSTL ) insiders, who had purchased shares in the previous 12 months were...
FRIENDSWOOD, Texas, November 14, 2023--Castle announced that data spanning its dermatologic portfolio of GEP tests was recently presented at the 2023 ASDS Annual Meeting.